Ben Hickey

As president, Ben is responsible for the leadership of RayzeBio including the strategic growth of the company’s differentiated actinium-based radiopharmaceutical platform to enable rapid development of programs and therapies for the benefit of patients around the world. 

With over 20 years of industry experience, Ben joined RayzeBio in 2024 following the acquisition of Mirati Therapeutics where he was most recently chief commercial officer and head of business development. Prior to Mirati, Ben was senior vice president, chief commercial officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy for the company’s oncology portfolio. Previously, Ben spent 17 years at Bristol Myers Squibb in various roles, including general manager, UK & Ireland, where he oversaw an organization of more than 300 people, and vice president Marketing, Immuno-Oncology. Ben received both his MBA and B.S. in management from St. John’s University in Queens, New York.